| 摘要 |
PCT No. PCT/EP96/03129 Sec. 371 Date Dec. 31, 1997 Sec. 102(e) Date Dec. 31, 1997 PCT Filed Jul. 17, 1996 PCT Pub. No. WO97/04005 PCT Pub. Date Feb. 6, 1997The invention concerns new cyclic peptides of general formula (I) in which the letters A to K signify residues of the following amino acids: A is substituted homothreonine of the general formula (II): R1-CH2CH(CH3)-CH(OH)-CH(NHCH3)-COOH in which R1 is n-propyl or propenyl in which the double bond is preferably in the trans configuration; B is alpha -aminobutyric acid, valine, norvaline or threonine; C is a D-amino acid of the general formula (III): CH3NH-CH(R)-COOH in which R is straight-chain or branched-chain C2-C6 alkyl, alkenyl or alkynyl, whereby these groups may be substituted by hydroxy, amino, C1-C4 alkylamino, C1-C4 dialkylamino, alkoxy or acyloxy, COOR2 or CONHR2 in which R2 is straight-chain or branched-chain C1-C4 alkyl X-R3 in which X is O or S and R3 is straight-chain or branched-chain C1-C4 alkyl, alkenyl or alkynyl and, when X is S, R3 may also by aryl or heteroaryl, halogen, preferably fluorine, cyano, CHR4R5 in which R4 is hydrogen, methyl, ethyl or phenyl and R5 is hydrogen, hydroxy, halogen (preferably fluorine), amino, C1-C4 alkylamino, C1-C4 dialkylamino, acyloxy (preferably acetyloxy), tert-butoxycarbonylamino-ethoxy-ethoxy-acetyloxy or alkoxycarbonyl (preferably butoxycarbonyl); D is N-methyl-gamma-hydroxyleucine or N-methyl-gamma-acetyloxyleucine; E is valine; F, I and J are each N-methylleucine; G is alanine; H is D-alanine or D-serine; and K is N-methylvaline. The invention also concerns the preparation of such peptides and their use in the prevention of infection by the human immunodeficiency virus (HIV).
|
